Ad hoc: Biofrontera AG: Licensing Agreement for AmeluzÂ® in Israel with Perrigo Israel Agencies Ltd.
Biofrontera AG /
Keyword(s): Misc. matters /
Ad hoc: Biofrontera AG: Licensing Agreement for AmeluzÂ® in Israel with Perrigo
Israel Agencies Ltd.
. Ad hoc announcement according to Â§ 15 WpHG. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Leverkusen, 6 January 2014 - Biofrontera Pharma GmbH, a fully-owned subsidiary
of Biofrontera AG, has today signed an agreement with Perrigo Israel Agencies
Ltd. for the marketing of Ameluz(Â®) and BF-RhodoLED(Â®) in Israel. In December
2011, Ameluz(Â®) received the centralized European approval as medicinal product
for the first-line treatment of mild and moderate actinic keratosis. Ameluz(Â®)
is used together with a red-light source, such as Biofrontera's BF-RhodoLED(Â®),
in photodynamic therapy (PDT), by which tumor cells in the skin are selectively
killed. The treatment results in high cure rates with outstanding cosmetic
result. The agreement includes profit sharing and milestone payments.
Perrigo Company plc is a global pharmaceutical company with fiscal year 2013
sales of approximately US$3.5 billion. Perrigo Israel is active in both
medicinal products and medical devices. It holds a leading position in the field
of dermatology in Israel.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via GlobeNewswire